Back to mobile site

Stifel Reiterates Buy Rating on Janux Therapeutics (JANX)

December 3, 2024 5:27 AM EST Send to a Friend
Stifel analyst Bradley Canino reiterated a Buy rating and $70.00 price target on Janux Therapeutics (NASDAQ: JANX).The analyst comments "Updated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login